RNA therapeutics to control fibrinolysis: review on applications in biology and medicine
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.04.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Francesca Ferraresso und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA; Michael Smith Laboratories, University of British Columbia, Vancouver, Britis…. Hauptthemen laut MEDLINE: Fibrinolysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Regulation of fibrinolysis, the process that degrades blood clots, is pivotal in maintaining hemostasis. Dysregulation leads to thrombosis or excessive bleeding. Proteins in the fibrinolysis system include fibrinogen, coagulation factor XIII, plasminogen, tissue plasminogen activator, urokinase plasminogen activator, α2-antiplasmin, thrombin-activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1, α2-macroglobulin, and others. While each of these is a potential therapeutic target for diseases, they lack effective or long-acting inhibitors. Rapid advances in RNA-based technologies are creating powerful tools to control the expression of proteins. RNA agents can be long-acting and tailored to either decrease or increase production of a specific protein. Advances in nucleic acid delivery, such as by lipid nanoparticles, have enabled the delivery of RNA to the liver, where most proteins of coagulation and fibrinolysis are produced. This review will summarize the classes of RNA that induce 1) inhibition of protein synthesis, including small interfering RNA and antisense oligonucleotides; 2) protein expression, including messenger RNA and self-amplifying RNA; and 3) gene editing for gene knockdown and precise editing. It will review specific examples of RNA therapies targeting proteins in the coagulation and fibrinolysis systems and comment on the wide range of opportunities for controlling fibrinolysis for biological applications and future therapeutics using state-of-the-art RNA therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Research Institute, Versiti Wisconsin, Milwaukee, Wisconsin, USA; Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada; Department of Biochemistry and Molecular Biology,…
- Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada; Cen…
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- Canadian Institutes of Health Research
- National Institutes of Health
Zitieren
APA
Ferraresso, F., Leung, J., & Kastrup, C. J. (2024). RNA therapeutics to control fibrinolysis: review on applications in biology and medicine. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.04.006
Vancouver
Ferraresso F, Leung J, Kastrup CJ. RNA therapeutics to control fibrinolysis: review on applications in biology and medicine. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.04.006
BibTeX
@article{Ferraresso2024,
author = {Ferraresso, Francesca and Leung, Jerry and Kastrup, Christian J},
title = {RNA therapeutics to control fibrinolysis: review on applications in biology and medicine},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.04.006}
}
EUVIMED